Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer

Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer

Objectives. To compare pathologic outcomes after treatment with gemcitabine and cisplatin (GC) versus methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) in the neoadjuvant setting. Methods. Data was retrospectively collected on 178 patients with T2-T4 bladder cancer who underwent radical c...

Full description

Bibliographic Details
Main Authors: Lee, Franklin C., Harris, William, Cheng, Heather H., Shenoi, Jaideep, Zhao, Song, Wang, Junfeng, Champion, Thomas, Izard, Jason, Gore, John L., Porter, Michael, Yu, Evan Y., Wright, Jonathan L.
Format: Online
Language:English
Published: Hindawi Publishing Corporation 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3871504/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3871504/

Similar Items